1. Home
  2. IPDN vs APRE Comparison

IPDN vs APRE Comparison

Compare IPDN & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

IPDN

Professional Diversity Network Inc.

HOLD

Current Price

$0.82

Market Cap

9.5M

Sector

Technology

ML Signal

HOLD

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.85

Market Cap

10.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IPDN
APRE
Founded
2003
2006
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.5M
10.6M
IPO Year
2012
2019

Fundamental Metrics

Financial Performance
Metric
IPDN
APRE
Price
$0.82
$0.85
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.10
AVG Volume (30 Days)
74.0K
304.2K
Earning Date
05-15-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.22
EPS
N/A
N/A
Revenue
$22,054,219.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.68
$0.55
52 Week High
$12.39
$2.22

Technical Indicators

Market Signals
Indicator
IPDN
APRE
Relative Strength Index (RSI) 40.02 50.36
Support Level N/A $0.57
Resistance Level $1.02 $0.98
Average True Range (ATR) 0.08 0.08
MACD -0.00 -0.01
Stochastic Oscillator 41.35 21.03

Price Performance

Historical Comparison
IPDN
APRE

About IPDN Professional Diversity Network Inc.

Professional Diversity Network Inc provides access to networking, training, educational, and employment services to its registered users. It has three operating segments: the TalentAlly Network segment, which maintains and operates job board software and hosts career fairs; the National Association of Professional Women (NAPW) segment, which is a women-only professional networking organization; the RemoteMore segment; and Corporate Overhead. The company generates the majority of its revenue from the TalentAlly Network Segment.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Share on Social Networks: